Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Free Report) were down 4% during trading on Wednesday . The company traded as low as $12.36 and last traded at $12.62. Approximately 28,642 shares were traded during mid-day trading, a decline of 37% from the average daily volume of 45,720 shares. The stock had previously closed at $13.14.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of Greenwich LifeSciences in a research note on Wednesday, February 28th.
Check Out Our Latest Research Report on GLSI
Greenwich LifeSciences Stock Up 6.3 %
Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) last released its earnings results on Monday, April 15th. The company reported ($0.21) earnings per share for the quarter. As a group, analysts forecast that Greenwich LifeSciences, Inc. will post -0.76 earnings per share for the current year.
Insider Buying and Selling at Greenwich LifeSciences
In other news, CEO Snehal Patel bought 3,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were bought at an average cost of $19.08 per share, with a total value of $57,240.00. Following the purchase, the chief executive officer now directly owns 5,350,777 shares in the company, valued at $102,092,825.16. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last 90 days, insiders have purchased 23,800 shares of company stock valued at $327,722. Corporate insiders own 52.86% of the company’s stock.
About Greenwich LifeSciences
Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
See Also
- Five stocks we like better than Greenwich LifeSciences
- 5 discounted opportunities for dividend growth investors
- 3 Stocks Leading the U.S. Agriculture Comeback
- How to Use the MarketBeat Excel Dividend Calculator
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What Are the FAANG Stocks and Are They Good Investments?
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.